DRUG
Amylin
The participants will receive continuous intravenous infusion of 20 mL (6 μg/min) of pramlintide (amylin) over 20 minutes.
Status
Not yet recruiting
Phase
Not applicable
Enrollment
21
Locations
1
Results
Not posted
Publications
8
Study summary
Pramlintide is a peptide analogue of human amylin which is a vasoactive signaling molecule involved in the pathogenesis of migraine. This study investigates whether pramlintide induces migraine attacks without aura in people with migraine without aura.
Amylin is a vasoactive substance that acts on vascular smooth muscle and can cause vasodilation. It is naturally present in the trigeminovascular system, an important structure involved in headache development. Recent studies indicate that intravenous infusion of pramlintide, an amylin analogue, can trigger migraine attacks in people with migraine. This study aims to determine whether intravenous pramlintide can induce migraine attacks without aura in individuals who experience migraine without aura. To test this, the investigators will conduct a randomized, double-blind, placebo-controlled, two-way crossover trial.
Interventions
DRUG
The participants will receive continuous intravenous infusion of 20 mL (6 μg/min) of pramlintide (amylin) over 20 minutes.
DRUG
The participants will receive continuous intravenous infusion of 20 mL of placebo (isotonic saline) over 20 minutes.
Timeline
First posted
Jan 14, 2026
Study start
Feb 2026
Primary completion
Oct 30, 2028
Study completion
Oct 30, 2028
Results posted
Not reported
Registry updated
Jan 14, 2026
Outcomes
Incidence of migraine attacks without aura
Time frame · 12 hours
The difference in the incidence of migraine attacks without aura between pramlintide and placebo during the 12-hour observational period after infusion start.
Headache intensity scores
Time frame · 12 hours
The secondary outcome is the difference in the area under the curve (AUC) for median headache intensity scores between pramlintide and placebo during the 12-hour observational period after infusion start.
Eligibility
Inclusion Criteria: * Age 18 to 65 years of age upon entry into screening * A body weight of 50 to 100 kg * History of migraine without aura for ≥12 months and in accordance with ICHD-3 * Between 1-5 monthly migraine days without aura on average across the 3 months prior to screening * Provision of informed consent prior to initiation of any study-specific activities/procedures Exclusion Criteria: * Any history of a primary or secondary headache disorder other than migraine without aura and infrequent episodic tension-type headache * Any history of moderate to severe traumatic brain injury * Any history of cardiovascular disease, including cerebrovascular diseases * Any history of pulmonary disease * Any other clinically significant disorders, conditions, or diseases that might impact the safety of the subject or interfere with the study's evaluation, procedures, or completion, aside from those mentioned above. This includes any relevant medical history or evidence that, in the opinion of the site investigator, might pose a risk to the subject or impact the validity of the study results * The subject is at risk of self-harm or harm to others as evidenced by past suicidal behavior * Female subjects of childbearing potential with a positive pregnancy test during any study visit * Cardiovascular disease of any kind, including cerebrovascular diseases * Hypertension (systolic blood pressure of ≥150 mmHg and/or diastolic blood pressure of ≥100 mmHg) prior to the start of infusion on the experimental day * Hypotension (systolic blood pressure of ≤90 mmHg and/or diastolic blood pressure of ≤50 mmHg) * Abnormalities on the electrocardiogram that, in the opinion of the site investigator, might pose a risk to the subject or impact the validity of the study results * Daily use of any medication other than contraceptives * Intake of any medication other than contraceptives within 48 hours of infusion start * Intake of caffeine, nicotine, and alcohol within 12 hours of infusion start * Headache of any intensity within 48 hours of infusion start * Migraine attack within 48 hours of infusion start * Aura within 48 hours of infusion start
Study locations
Denmark. Showing up to 24 locations stored in the fast local snapshot.
Rigshospitalet Glostrup
Glostrup Municipality, Denmark
Publications
Related trials
University of Copenhagen · Healthy Adult Participants · Bone Physiology
Not applicable
Not yet recruiting
15
2026-07
Oregon Health and Science University · Type 1 Diabetes
Not applicable
Completed
33
2026-06
Boston University · Alzheimer Disease · Mild Cognitive Impairment
Early Phase 1
Active, not recruiting
57
2026-05
Esbjerg Hospital - University Hospital of Southern Denmark · Obesity · Appetite Regulation
Phase 2 / Phase 3
Withdrawn
0
2026-04
University Hospital, Gentofte, Copenhagen · Obesity & Overweight
Not applicable
Recruiting
18
2026-04
Danish Headache Center · Headache Disorders, Secondary · Brain Diseases
Not applicable
Not yet recruiting
21
2026-01
McGill University Health Centre/Research Institute of the McGill University Health Centre · type1diabetes · Diabetes Mellitus, Type 1
Phase 2 / Phase 3
Unknown
30
2024-04
Xeris Pharmaceuticals · Diabetes Mellitus, Type 1 · Insulin-dependent Diabetes Mellitus
Phase 2
Completed
18
2024-03
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.